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The Protein Data Bank (PDB) was established in 1971 as a repository for the three dimensional struc-
tures of biological macromolecules. Since then, more than 85000 biological macromolecule struc-
tures have been determined and made available in the PDB archive. Through analysis of the
corpus of data, it is possible to identify trends that can be used to inform us abou the future of struc-
tural biology and to plan the best ways to improve the management of the ever-growing amount of
PDB data.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The establishment of the Protein Data Bank (PDB) in 1971 [1]
was the culmination of several years of community discussion
about how best to archive and distribute the results of structure
determinations of biological macromolecules. Led at ﬁrst byWalter
Hamilton and then by Tom Koetzle at Brookhaven National Labora-
tory, the young resource solicited data from the early pioneers in
the ﬁeld and distributed them on magnetic tapes to the scientists
who requested them [2]. In 1989, following many years of discus-
sion within the structural biology community, guidelines were
established for the timing of data deposition [3]. These guidelines
led to the now almost universal journal requirement that data
are deposited before a manuscript is accepted and then released
upon publication.
In 1998, the management of the PDB was taken over by the Re-
search Collaboratory for Structural Bioinformatics (RCSB) [4]. At
about the same time, data centers at the European Bioinformatics
Institute in the United Kingdom (now PDBe [5,6]) and Osaka Uni-
versity in Japan (now PDBj [7]) expanded from being distribution
sites to also accepting and processing data. The collaboration
among the three sites was formalized in 2003 with the formation
of the Worldwide PDB (wwPDB) [8,9]. In 2006, BioMagResBankjoined the organization [10]. The mission of the wwPDB is to en-
sure that standards are set and met for data representation and
data quality in the archive. To help accomplish this, the wwPDB
established Task Forces of experts in X-ray crystallography, nuclear
magnetic resonance (NMR) spectroscopy, 3D electron microscopy
(3DEM), and small angle scattering. These Task Forces make rec-
ommendations about which data should be collected and how
these data should be best validated [11,12].
Data are reviewed across the archive on a regular basis and
remediated when appropriate [13,14]. In recent years, atom and
residue nomenclatures have been aligned with International Union
of Pure and Applied Chemistry (IUPAC) standards. An enriched
Chemical Component Dictionary has enhanced the representation
of small molecule ligands in the PDB archive. Most recently, the
representation of complex peptides has been standardized [15].
The PDB is a well-curated archive that evolves with new devel-
opments in structural biology. In this paper, the current contents of
the archive are analyzed in order to quantify some of these devel-
opments and better understand the trends.
2. Trends
2.1. Growth patterns
The holdings in the PDB continue to grow (Fig. 1) at a rate
slightly greater than the growth rate of publications in PubMed
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Fig. 1. Growth of the PDB archive. (A) Depositions per year are shown in black and total released entries available in gray on a logarithmic scale. Reprinted from Berman [46]
with permission from Wiley; (B) growth of depositions from X-ray crystallography. Depositions per year are shown in black and total released entries available in light gray;
(C) growth in depositions from NMR. Depositions per year are shown in black and total released entries available in light gray; (D) growth in depositions from 3DEM.
Depositions per year of 3DEM maps are shown in light gray and depositions per year of model coordinates in black.
H.M. Berman et al. / FEBS Letters 587 (2013) 1036–1045 1037[16]. As early as 1978, Dick Dickerson had modeled the growth of
crystallographic entries as exponential, n = exp(0.19 y), where n is
the number of new structures per year and y is the number of years
since 1960. Overall, this model is largely correct [17]. More re-
cently, Cele Abad-Zapatero reanalyzed the growth statistics in
more detail and discovered that the overall growth rate has re-
mained surprisingly close to Dickerson’s prediction through
2005, with some decrease in the growth rate between 2006 and
2010 [18]. This is consistent with an analysis of PDB depositions
that shows a yearly acceleration in data deposition, with the nota-
ble exception of 2008. Based upon the rate of increase since the
year 2000, our analysis predicts that PDB holdings will increase
1.5-fold between 2012 (current holdings of 85000) and the end
of 2017 (projected holdings of 134000).
The usage of PDB data is also growing. There were 380 million
downloads of data from the wwPDB FTP sites in 2011 as compared
to 226 million downloads in 2008. Download statistics for the
overall archive and for individual entries are available from the
wwPDB website (http://www.wwpdb.org/downloadStats.php).0
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Fig. 2. Number of PDB entries depData are also accessed from the individual wwPDB member web-
sites. The RCSB PDB website is accessed by about 250000 unique
visitors per month from 140 countries. Around 750 gigabytes of
data are transferred each month from the website. The breadth
of PDB usage can be seen in the more than 11000 citations to
the original RCSB PDB reference [4] in journal subject areas ranging
from medical informatics and surgery to art to physics
(wokinfo.com).
Fig. 2 shows an overall increase in depositions from each conti-
nent, but with a notable dip in 2008. Since then, the number of
depositions has resumed growing: North American depositions
are continuing to grow steadily; despite a slight decline in 2011,
analysis of 2012 statistics indicates that European depositions
are growing overall; and in Asia, a slower growth rate of Japanese
depositions is compensated for in part by a faster growth rate of
Chinese depositions.
The number of structures released without a corresponding
publication is growing. Information about publications associated
with PDB entries is updated regularly. Ninety-eight percent of20
09
20
10
20
11
North America
Europe
Asia
South America
Australia/New Zealand
Africa
osited per year by continent.
01000
2000
3000
4000
5000
6000
19
90
19
92
19
94
19
96
19
98
20
00
20
02
20
04
20
06
20
08
20
10
N
um
be
r o
f d
ep
os
ite
d 
en
tri
es
Year
Synchrotron 
Home Source
0
200
400
600
800
1000
1200
1400
19
96
19
98
20
00
20
02
20
04
20
06
20
08
20
10Year
(A)  (B)  
N
um
be
r o
f d
ep
os
ite
d 
en
tri
es
 SAD phasing
MAD phasing
Fig. 3. Use of synchrotron radiation in the PDB. (A) The number of structures determined using synchrotron radiation deposited per year is shown in grey; the number using
home-laboratory sources in black. This plot shows that while the use of home sources for X-ray structure determination has remained roughly constant, the use of
synchrotron sources has increased rapidly. Reprinted from Berman [46] with permission from Wiley; (B) use of SAD (in black) and MAD (in gray) phasing in PDB entries
deposited per year. After an initial growth in MAD phasing, SAD phasing has become more widely used.
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Fig. 4. 3DEM structures released in the PDB and EMDB [25] by resolution range and reconstruction method. Structures archived in the PDB were represented in this plot
exclusively by method and not by mixed type. ‘‘Helical’’ represents the traditional layer-line approach, and ‘‘2D Crystal’’ denotes electron crystallography. Helical structures
solved using the single particle approach are grouped under ‘‘Single Particle’’; two-dimensional crystal structures solved exclusively using subtomogram averaging with no
calculation of structure factors from images or measurement of structure factor intensities were grouped under ‘‘Subtomogram’’. The graph represents 1148 total deposited
EM structures encompassing 1146 maps deposited to EMDB and 415 models deposited to PDB. These include 840 map-only structures, 277 maps with one or more associated
PDB models, and 31 electron crystallography PDB entries.
1038 H.M. Berman et al. / FEBS Letters 587 (2013) 1036–1045the structures released by the PDB in 2001 were published in jour-
nals. In 2011, that percentage decreased to 74%. Part of the reason
for this drop was the establishment of the Protein Structure Initia-
tive (PSI [19]), which requires data release within one month of
structure determination. As a result of this requirement, the per-
centage of PSI entries with corresponding publications is necessar-
ily much lower than the rest of the PDB archive. Overall,
approximately 20% of PSI structures have an associated citation,
as compared to almost 80% of all PDB depositions released between
2001 and 2011 [20].
2.2. Structure determination methods
Most structures in the PDB – currently 88% of the entire archive
– have been determined using X-ray crystallography. There has
been steady growth in the number of these depositions (Fig. 1B).
Synchrotron radiation is now the predominant source of X-rays
used for data collection (Fig. 3A). The use of either Single-wave-
length Anomalous Dispersion (SAD) or Multi-wavelength Anoma-
lous Dispersion (MAD) methods for phasing peaked in 2009.
Since 1996, when MAD and SAD began to be used, approximately
15% of all X-ray structures deposited through 2011 have been
phased using one of these methods (Fig. 3B). Molecular replace-ment or Fourier phasing methods continue to be used for the
majority of X-ray structure determinations.
The average resolution of X-ray structures has remained con-
stant at about 2.0 Å. However, with the large volume of data avail-
able, there are now substantial numbers of structures determined
to very high resolution, including at least one virus structure [21].
At the same time, as more large macromolecular machines are
being studied using X-ray methods, there are many examples of
very low-resolution structures [22–24].
The use of NMR methods for structure determination began in
the 1980s (Fig. 1C). After an initial period of growth, the number
of structures deposited per year began to decrease in 2008. The
average molecular weight for NMR depositions is about 10000
daltons.
Electron microscopy (3DEM) has been used for structure deter-
mination since the 1990s, and the number of map and coordinate
depositions is increasing (Fig. 1D) [25]. The rapid growth in 3DEM
map depositions points towards future growth in deposition of
model coordinates from this method. The most popular 3DEM
method is single particle reconstruction (for structures such as
viruses), with some representation of helical reconstruction, elec-
tron crystallography, and subtomogram averaging methods
(Fig. 4).
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Fig. 5. Growth in the size and complexity of PDB entries. (A) Average molecular weight of entries released each year for structures determined by X-ray crystallography (for
the asymmetric unit; in grey) and NMR (in black). Calculations excluded water and counted extremely large structures as single entries. For viruses and entries that used non-
crystallographic symmetry (NCS), molecular weights for the full asymmetric unit were calculated by multiplying the molecular weight of the explicit polymer chains by the
number of NCS operators. The large increase shown in 1984 was due to the release of the tomato bushy stunt virus 2tbv [47]; (B) the number of PDB entries, total related
polymer chains, and protein sequences (with 50% redundancy as calculated using blastclust [48]) available in the archive each year; (C) the number of unique non-polymer
ligands released each year (a single entry may have several ligands). There are three notable peaks: 73 structures with an inhibitor/antibiotic were released in 1994, the
majority of which are thrombin inhibitors and renin inhibitors; 130 structures in 2006, the majority of which are thrombin inhibitors and other protease inhibitors; and 140
structures in 2011, the majority of which are protease inhibitors, including caspase inhibitors; (B and C) reprinted from Berman [46] with permission from Wiley; (D) the
number of peptide-like inhibitor/antibiotic entries released per year.
Table 1
Proteins most-frequently deposited in the PDB. Proteins were selected by creating clusters of structures with 90% sequence identity. To split the PDB roughly in half, August 2007
was used as the halfway point (42888 protein-containing entries (53.1% of the current archive) were available at the end of July 2007, compared to 80800 available at the end of
July 2012).
Cluster
rank
Protein clusterb Total number of PDB
entries
Number released before
Aug 2007
Number released after
Aug 2007
Percentage released after
Aug 2007 (%)
1 T4 lysozyme 531 441 90 16.9
2 HIV protease 497 271 226 44.5
3 Carbonic anhydrase II 408 218 190 46.6
4 Egg-white lysozyme 400 286 114 28.5
5 Trypsin 380 269 111 29.2
6 Thrombin (complex of heavy and light chains) 316 218 98 31.0
7a Human MHC-I antigen (complex with beta-2-
microglobulin)
312 134 178 57.0
8 Myoglobin 232 179 53 22.8
9 Cyclin-dependent kinase 2 217 134 83 38.2
10 Hemoglobin (complex of alpha and beta
subunits)
204 174 30 14.7
11 Human lysozyme 203 196 7 3.4
12 Antibody chain 201 84 117 58.2
13 MAP Kinase 14 194 53 141 72.7
14 Ribonuclease A 193 126 67 34.7
15 Beta-secretase 1 190 36 154 81.1
16 Thermonuclease 181 98 83 45.9
17 Insulin (complex of A and B chains) 173 105 68 39.3
a Structures of the human MHC-I complex were grouped using 90% sequence identity on the beta-2-microglobulin component, not MHC-I antigen themselves, due to the
sequence diversity of the antigens.
b Protein sequence search target sources for each cluster: bacteria phage T4: 1; HIV: 2; human: 3, 6, 7, 9, 10, 11, 13, 15, 17; chicken: 4; bovine: 5, 14; sperm whale: 8;
various: 12, Staphylococcus aureus: 16.
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Fig. 6. Examples of molecules in the PDB that are or have been used as drugs, shown in ball and stick. For each, the corresponding 3-character code from the Chemical
Component Dictionary is listed. Blockbuster drugs shown are (A) atorvastatin bound to HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway (PDB ID
1hwk [49]) and (B) clopidogrel bound to cytochrome P450 2B4, which activates the prodrug (PDB ID 3me6 [50]); peptidomimetic inhibitors shown are (C) remikiren bound to
human renin (PDB ID 3d91 [51]) and (D) saquinavir bound to HIV protease (PDB ID 1hxb [52]); (E) aminoglycoside antibiotic shown is neomycin bound to extended duplex
RNA (PDB ID 3c7r [53]); (F) peptide-like antibiotic/antitumor agent actinomycin D structure (PDB ID 1a7y [54]).
1040 H.M. Berman et al. / FEBS Letters 587 (2013) 1036–10452.3. Chemistry
2.3.1. Overall
More than 90% of the PDB’s holdings are proteins. Over the
years the average molecular weight of the asymmetric unit for
crystal structures has increased from less than 30000 daltons to
over 110000 daltons (Fig. 5A). The number of biopolymer chains
has increased at a somewhat faster rate than the number of entries
(Fig. 5B). The number of non-redundant sequence clusters is also
growing constantly. Analysis of the top 20 sequence clusters in
the PDB shows that the most studied proteins overall are lysozyme,
human immunodeﬁciency virus (HIV) protease, carbonic anhy-
drase, and trypsin. However, the trends in recent years have chan-
ged, with HIV protease, major histocompatibility complex (MHC),
carbonic anhydrase, beta secretase, and mitogen-activated protein
(MAP) kinase being the most commonly deposited protein struc-
tures since 2007 (Table 1). This is most likely because of the impor-
tant roles these proteins play in biomedical research.
The number of ligands available in the PDB continues to in-
crease; there are now more than 14,000 ligands in the wwPDBChemical Component Dictionary, including some important drugs
(Figs. 5C, 6A and B). Of the 85000 entries currently available in
the PDB, 70% are complexes containing small molecule ligands.
Peptide antibiotics and peptide inhibitors compose a special class
of ligands, many of which have pharmaceutical value and whose
numbers continue to increase (Figs. 5D and 6C,D,F). In addition
to the peptide-like antibiotics, there are several examples in the ar-
chive of other complex antibiotics such as aminoglycosides
(Fig. 6E).
2.3.2. Nucleic acid-containing entries
There are three major classes of nucleic acid-containing entries
in the PDB archive: RNA, DNA, and protein–nucleic acid complexes.
Nucleic acid crystallography took longer to become established
than protein crystallography in large part due to the difﬁculties
of isolating and purifying samples. The ﬁrst nucleic acid structure
to be deposited in the PDB was yeast phe tRNA [26,27] (Fig. 7A).
The ﬁrst DNA structure determined was a short fragment of left-
handed Z-DNA [28]. The ﬁrst full turn of B-DNA was published in
1981 [29] (Fig. 7C). There was steady growth in the number of
Fig. 7. Examples of some of the early nucleic-acid containing structures. (A) Yeast tRNA-Phe (PDB ID 4tna [55]); (B) hammerhead ribozyme (PDB ID 1hmh [30]); (C) B-DNA
dodecamer (PDB ID 1bna [29]); (D) complex of the DNA operator and the phage 434 repressor (PDB ID 2or1 [56]); (E) hepatitis delta virus ribozyme (PDB ID 1drz [57]).
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Fig. 8. Growth in the number of depositions per year for nucleic acid-containing
entries.
H.M. Berman et al. / FEBS Letters 587 (2013) 1036–1045 1041DNA structures deposited in the PDB until the mid-1990s, when
the growth rate plateaued. Around that time, ribozymes were dis-
covered [30] (see example in Fig. 7B), and RNA structure deposi-
tions increased and then leveled off. In the 1980s, the ﬁrst
structures of protein-DNA complexes were deposited, followed
by the ﬁrst single-crystal protein–RNA complex structures in the
early 1990s (see examples in Figs. 7D and E, respectively).The growth rate of the deposition of protein–nucleic acid com-
plexes continues to increase (Fig. 8), partly as a consequence of
continuing investigations of the structure of ribosomes complexed
with drugs.
2.3.3. Carbohydrate-containing entries
Carbohydrates are known to play key roles in energy genera-
tion, cell signaling, cellular recognition, and cellular and extracellu-
lar matrix formation [31]. While the building blocks, interactions,
structures, and organization of proteins and nucleic acids are rela-
tively well understood, carbohydrates have yet to be fully charac-
terized at either the structural or functional level. In addition,
carbohydrate polymers, unlike proteins and nucleic acids, do not
have a standard backbone structure and are not synthesized based
on a genetic code. Carbohydrate polymers in protein glycosylations
are subject to the activity of enzymes and to the availability of spe-
ciﬁc saccharide substrates, leading to considerable variability.
More than 7000 PDB entries contain carbohydrate polymers
and/or individual saccharides. They are present as single sugars
(monosaccharides) that are either unbound (see example in
Fig. 9A) or covalently linked to proteins (as seen in some glycopro-
teins) and as polymers of various lengths that are either unbound
(structural components or substrates of speciﬁc enzymes) or cova-
lently linked to proteins (glycoproteins, example in Fig. 9B). While
monosaccharides are key components of nucleotides, mono- and
polysaccharides also form key components of several antibiotics
Fig. 9. Examples of carbohydrate-containing entries, with the carbohydrates shown in ball and stick. (A) Single unbound monosaccharide, rhamnose, in the structure of
rhamnose-binding lectin, a pattern recognition protein with a role in innate immunity (PDB ID 2zx2 [58]); (B) polymeric glycoprotein in glycosylated human lactotransferrin
N2 fragment (purple) in complex with legume lectin chains (cyan and red, PDB ID 1lg2 [59]); (C) polysaccharide antitumor drug mithramycin bound to a DNA fragment (PDB
ID 1bp8 [32]); (D) mixed polymers: bacterial cell wall muramyl peptide (peptidoglycan) bound to legume isolectin chains (cyan and red, PDB ID 1loc [33]).
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1042 H.M. Berman et al. / FEBS Letters 587 (2013) 1036–1045such as mithramycin (Fig. 9C, [32]) and other biologically impor-
tant molecules, such as peptidoglycans (Fig. 9D, [33]), proteogly-
cans, and glycolipids. Because the PDB was originally designed as
an archive for proteins, some important components of macromol-
ecules such as carbohydrates are not well deﬁned, making search
and analysis of them difﬁcult. This situation is recognized and is
being remedied.2.3.4. Complex biological assemblies
The PDB contains many examples of multi-subunit biological
assemblies (Fig. 10). Analysis shows that fewer structures have an
odd number of subunits than have an even number. Some assem-
blies are particularly overrepresented, such as those with 6, 8, 12,
24, and n  60 subunits. One plausible reason for this distribution
is that the over-represented values correspond to complexes with
Fig. 11. Strongly interconnected research community built around early virus structures. The network diagram shown at center illustrates author relationships among
icosahedral virus structures deposited in the PDB. Structures are represented as nodes (circles); a curved line connects pairs of nodes where one or more authors are shared in
common. The highest connectivity densities deﬁne thirteen major author clusters. Color key/cluster principle investigators: red: M.G. Rossmann, T.S. Baker; blue: L. Liljas,
S.E.V. Phillips, P.G. Stockley; cyan: J.E. Johnson; purple: S.C. Harrison, J.M. Hogle; light green: D.I. Stuart, E.E. Fry, Z. Rao; yellow: M. Agbandje-McKenna; light blue: M.R.N.
Murthy; orange: H. Zhou; dark cyan: A. McPherson; dark red: M.S. Chapman; pink: T. Tsukihara; dark green: W. Chiu; grey: E. Arnold. The nodes belonging to the ﬁrst ﬁve
structures are identiﬁed for reference: tomato bushy stunt virus (PDB ID 2tbv [47]), southern bean mosaic virus (PDB ID 4sbv [63]), satellite tobacco necrosis virus (PDB ID
2buk [37]), rhinovirus (PDB ID 4rhv [64]), and poliovirus (PDB ID 2plv [65]). Gephi [66] was used for cluster analysis of 375 icosahedral virus PDB entries connected by 364
deposition authors.
H.M. Berman et al. / FEBS Letters 587 (2013) 1036–1045 1043regular point symmetries, such as the n  60 icosahedral viruses
[14]. Further analysis of these assemblies yields some additional
interesting observations. Multi-subunit assemblies can be used to
facilitate the formation of nanoparticles within their cavities, as
with octahedral ferritin (PDB ID 2z6m [34]). In other cases, nano-
scale structures have been designed via self-assembly, including
a 13 nm octahedral cage (PDB ID 4ddf [35]) and a 16 nm cavity
with a tetrahedral arrangement (PDB ID 3vdx [36]).
The ﬁrst atomic structures of viruses were published about
35 years ago [37], and there are now about 400 virus structures
in the PDB. The vast majority are icosahedral viruses solved by
either X-ray crystallography or cryo-electron microscopy. Because
success in this distinct area of structural biology critically depends
on expertise in highly specialized methods [38–41], it is perhaps
not surprising that it is practiced by a relatively small and inter-
connected group of scientists worldwide. Network cluster analysis
was used to investigate interconnectedness and growth of this re-search community relative to the ﬁrst structures determined be-
tween 1978 and 1985. The early structures directly nucleated
three major author clusters that have each contributed between
30 and 100 icosahedral virus structures to the PDB (Fig. 11: central
blue, right purple, and lower red clusters). The community has now
evolved into thirteen distinct author clusters; most of these are
strongly interconnected by several entries with shared deposition
authors.
2.4. Looking forward
Structural biology is unique in that the PDB archive provides a
quantitative indicator of research productivity. Our analysis of
these trends shows that the PDB has had an overall steady growth
since its inception in 1971. The slight decline in the number of
depositions in 2008 coincides with the discontinuation of a major
program in Japan [42] as well as a decline in the use of NMR for
1044 H.M. Berman et al. / FEBS Letters 587 (2013) 1036–1045structure determination. However, other factors such as global
economic developments and changes in science funding may also
be involved.
Analyses of these trends may help inform development of many
aspects of the archive such as the data dictionaries, annotation
practices, software development, and remediation efforts. For
example, the current development of a Common Tool for Deposi-
tion and Annotation will allow the wwPDB to manage an increased
data load without an increase in resources [43]. This tool will pro-
vide for distribution of the data load worldwide and incorporates
the best practices for annotation developed by the wwPDB.
As another example, the increased complexity and size of the
entries being deposited has led to the adoption of the PDBx format,
which has far fewer restrictions than the legacy PDB format
[44,45]. Current work with structure determination software
developers to incorporate PDBx ensures that data will be input
and exported from the PDB without loss of information. In addi-
tion, efforts to review and remediate special categories of entries
such as those containing complex peptides or carbohydrates will
improve the usability of the PDB by other scientists. Similarly,
the diversity of methods used for structure determination had
led to the creation of Task Forces that are making recommenda-
tions for data collection and validation.
These trends also inform the development of external resources.
The decline in the percentage of publications with accompanying
depositions strongly suggests the need to consider data as a type
of publication. This is, in fact, being done by the Web of Knowl-
edge’s Data Citation Index (wokinfo.com).
Continued surveillance and analysis of the PDB holdings can
provide new directions and opportunities for structural biology
and will also allow the archive to evolve along with the science
it represents.
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